Abstract: The invention relates to multi-epitopic peptide compounds obtained from PSA, HwB and LmLRAB proteins of Leishmania as well as to pharmaceutical compositions and vaccines for use against one or more leishmaniases.
Type:
Grant
Filed:
May 29, 2019
Date of Patent:
January 24, 2023
Assignees:
INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT, INSTITUT PASTEUR DE TUNIS
Inventors:
Rachel Bras Gonçalves, Jean-Loup Lemesre, Amel Garnaoui, Elodie Petitdidier-Lesin
Abstract: The present invention relates to lebecetin, a functional variant or fragment thereof, for use as neovascularization inhibitor, in particular in the treatment of neovascular diseases such as ocular diseases, cancers or inflammatory disorders with a neovascular component.
Type:
Grant
Filed:
December 12, 2017
Date of Patent:
December 7, 2021
Assignees:
SARBONNE INIVERSIÉ, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MEDICALE), INSTITUT PASTEUR DE TUNIS
Abstract: The invention relates to multi-epitopic peptide compounds obtained from PSA, HwB and LmLRAB proteins of Leishmania as well as to pharmaceutical compositions and vaccines for use against one or more leishmaniases.
Type:
Application
Filed:
May 29, 2019
Publication date:
July 15, 2021
Applicants:
INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT, INSTITUT PASTEUR DE TUNIS
Inventors:
Rachel Bras Gonçalves, Jean-Loup Lemesre, Amel Garnaoui, Elodie Petitdidier-Lesin
Abstract: The invention relates to the field of combating leishmaniases. Said invention results from the isolation, from wild isolates of Leishmania major, of a protein-coding gene known as LmPDI which has two regions that are identical to the sequence (Cys-Gly-His-Cys) of the potential active site of the protein disulphide isomerase (PDI). The LmPDI protein is predominantly expressed in the most virulent isolates of the parasite. Said protein forms a novel therapeutic target for developing anti-leishmaniasis medicaments and a novel element that can be used in the composition of immunogenic, and possibly vaccinating, preparations which are intended to protect a human or animal host against Leishmania.
Type:
Grant
Filed:
March 27, 2008
Date of Patent:
May 6, 2014
Assignees:
Institut Pasteur de Tunis, Institut Pasteur
Inventors:
Yosser Ben Achour, Mehdi Chenik, Hechmi Louzir, Koussay Dellagi
Abstract: The invention concerns an immunogenic composition comprising: i) an antigenic polypeptide consisting of a fragment of the protein histone H2B of Leishmania, said fragment including the N-terminal region of said protein histone H2B, and ii) an adjuvant stimulating the immune response.
Type:
Grant
Filed:
May 8, 2008
Date of Patent:
October 8, 2013
Assignees:
Institut Pastuer, Institut Pasteur De Tunis
Inventors:
Mehdi Chenik, Hechmi Louzir, Koussay Dellagi
Abstract: The invention relates to the use of a DEAD-box RNA helicase from a yeast, a mammal, Leishmania infantum, or fragments thereof for inducing the production of cytokines by a peripheral blood mononuclear cell (PBMC) of a mammal, and to the applications thereof.
Type:
Application
Filed:
June 5, 2009
Publication date:
December 15, 2011
Applicants:
INSTITUT PASTEUR DE TUNIS, INSTITUT PASTEUR
Abstract: The present invention relates to new proteins of Leishmania major and to therapeutical and diagnostic applications thereof. More particularly, the present invention relates to excreted/secreted polypeptides and polynucleotides encoding same, compositions comprising the same, and methods of diagnosis, vaccination and treatment of Leishmaniasis.
Type:
Grant
Filed:
April 7, 2006
Date of Patent:
February 15, 2011
Assignees:
Institut Pasteur, Institut Pasteur De Tunis
Inventors:
Mehdi Chenik, Sami Lakhal, Hechmi Louzir, Koussay Dellagi
Abstract: The invention relates to the field of combating leishmaniases. Said invention results from the isolation, from wild isolates of Leishmania major, of a protein-coding gene known as LmPDI which has two regions that are identical to the sequence (Cys-Gly-His-Cys) of the potential active site of the protein disulphide isomerases (PDI). The LmPDI protein is predominantly expressed in the most virulent isolates of the parasite. Said protein forms a novel therapeutic target for developing anti-leishmaniasis medicaments and a novel element that can be used in the composition of immunogenic, and possibly vaccinating, preparations which are intended to protect a human or animal host against Leishmania.
Type:
Grant
Filed:
December 12, 2003
Date of Patent:
April 20, 2010
Assignees:
Institut Pasteur, Institut Pasteur de Tunis
Inventors:
Yosser Ben Achour, Mehdi Chenik, Hechmi Louzir, Koussay Dellagi
Abstract: A method for the production of high-level soluble human recombinant interferon alpha protein (rhuIFN?) in E. coli and vectors useful for such a production which comprises: (1) transforming an E. coli selected in the group consisting of E. coli protease deficient host strains, and E. coli reductase deficient host strains, with a recombinant expression vector comprising the sequence encoding the glutathione-S-transferase (GST), a junction sequence including a recognition site for a specific protease and a sequence able to encode an interferon alpha (IFN alpha) protein under the control of an inducible promoter, said vector encoding a GST-IFN alpha fusion protein; (2) expressing said interferon alpha protein in conditions comprising the induction of the expression with 0.1 mM-0.5 mM IPTG and a growth temperature of 25° and/or 37° C., depending on said E. coli strain; and (3) isolating the expressed IFN alpha protein.
Type:
Application
Filed:
April 10, 2008
Publication date:
October 15, 2009
Applicants:
INSTITUT PASTEUR, Institut Pasteur de Tunis